Goodwin Advises Bionyra Pharma on $165 million Oversubscribed Series A and In-Licensing of Multiple Next-Generation Biologics
July 02, 2026
July 02, 2026
BOSTON, Massachusetts, July 2 [Category: BizLaw/Legal] -- Goodwin, a law firm, posted the following news release:
* * *
Goodwin Advises Bionyra Pharma on $165 million Oversubscribed Series A and In-Licensing of Multiple Next-Generation Biologics
*
A multidisciplinary global Life Sciences team advised Bionyra Pharma on the company's launch and its $165 million oversubscribed Series A financing co-led by Jeito Capital and Sofinnova Partners. . . .
* * *
Goodwin Advises Bionyra Pharma on $165 million Oversubscribed Series A and In-Licensing of Multiple Next-Generation Biologics
*
A multidisciplinary global Life Sciences team advised Bionyra Pharma on the company's launch and its $165 million oversubscribed Series A financing co-led by Jeito Capital and Sofinnova Partners. . . .